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Abstract 
 
Hydrogen sulfide (H2S) is a crucial signaling molecule involved in several physiological and 
pathological processes. Nonetheless, the role of this gasotransmitter in the pathogenesis and 
treatment of neuropathic pain is controversial. 
The aim of the present study was to investigate the pain relieving profile of a series of slow 
releasing H2S donors (the natural allyl-isothiocyanate and the synthetics phenyl- and 
carboxyphenyl-isothiocyanate) in animal models of neuropathic pain induced by paclitaxel or 
oxaliplatin, anticancer drugs characterized by a dose-limiting neurotoxicity. The potential 
contribution of Kv7 potassium channels modulation was also studied. 
Mice were treated with paclitaxel (2.0 mg kg-1) i.p. on days 1, 3, 5 and 7; oxaliplatin (2.4 mg kg-1) 
was administered i.p. on days 1-2, 5-9, 12-14. Behavioral tests were performed on day 15. In both 
models, single subcutaneous administrations of H2S donors (1.33, 4.43, 13.31 µmol kg-1) reduced 
the hypersensitivity to cold non-noxious stimuli (allodynia-related measurement). The prototypical 
H2S donor NaHS was also effective. Activity was maintained after i.c.v. administrations. On the 
contrary, the S-lacking molecule allyl-isocyanate did not increase pain threshold; the H2S-binding 
molecule hemoglobin abolished the pain-relieving effects of isothiocyanates and NaHS. The anti-
neuropathic properties of H2S donors were reverted by the Kv7 potassium channel blocker XE991. 
Currents carried by Kv7.2 homomers and Kv7.2/Kv7.3 heteromers expressed in CHO cells were 
potentiated by H2S donors. 
Sistemically- or centrally-administered isothiocyanates reduced chemotherapy-induced neuropathic 
pain by releasing H2S. Activation of Kv7 channels largely mediate the anti-neuropathic effect. 
 
 
Keywords: chemotherapy-induced neuropathic pain; H2S donors; Kv7 channels; isothiocyanate; 
retigabine 
 
Abbreviations: A-ITC, allyl isothiocyanate; A-IC, allyl isocyanate; CAT, cysteine 
aminotransferase; CBS, cystathionine-β-synthase; CMC, carboxymethyl cellulose; CO, carbon 
monoxide; CP-ITC, 3-carboxyphenyl isothiocyanate; CSE, cystathionine-γ-lyase; Hb, hemoglobin; 
H2S, hydrogen sulphide; 3MST, 3-mercaptopyruvate sulfurtransferase; NaHS, sodium hydrosulfide 
hydrate; NO, nitric oxide; PEG, polyethylene glycol; P-ITC, phenyl isothiocyanate; TEA, 
tetraethylammonium. 
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1. Introduction 
H2S is historically known as a natural chemical hazard. Nowadays H2S is considered a 
gasotransmitter in the mammalian body, like NO and CO, contributing to many physiological and 
pathological processes (Wang, 2002). It is endogenously produced mostly from L-cysteine and 
homocysteine through CSE, CBS and by a third pathway catalyzed by 3MST along with CAT 
(Shibuya et al. 2009). H2S can also be generated by sulfate-reducing bacteria in the intestinal lumen 
(Roediger et al., 1997). CBS is preferentially expressed in the hippocampus and cerebellum (Abe 
and Kimura, 1996), mainly localized in astrocytes and microglial cells (Enokido et al., 2005). 
Despite the high level of CSE in the cardiovascular system, the enzyme was also found in the 
nervous tissue in microglial cells (Lee et al., 2006) and in spinal cord- (Distrutti et al., 2006) and 
cerebellar granule-neurons (Garcia-Bereguiain et al., 2008). Also 3MST is present in neurons and 
astrocytes (Shibuya et al., 2009; Zhao et al., 2013).  
In the nervous system, H2S is involved in synaptic modulation by interacting with ion channels, 
second messengers and modifying sulfhydryl groups of proteins (Wallace and Wang, 2015). A 
major role in redox balance, mitochondrial bioenergetics, apoptosis and inflammatory processes 
(Kamat et al., 2015) leads to H2S relevance in memory, cognition and learning (Nagpure and Bian, 
2015) as well as in neuroprotection (Paul and Snyder, 2015).  
The role of H2S in pain modulation is controversial: conflicting data suggest that it is both 
pronociceptive (mainly through Cav3.2 T-type Ca2+ channels and transient receptor potential 
ankyrin 1 – TRPA1 channels; Terada and Kawabata, 2015) and anti-nociceptive (Wallace and 
Wang, 2015) depending on the models used and the types and doses of H2S donors or modulators 
used. Nonetheless, several studies have suggested significant pain relieving effects of H2S donors 
against neuropathic and visceral pain (Distrutti et al., 2006; Lin et al., 2014; Kida et al., 2015). 
Recently, some isothiocyanate derivatives, slow releasing H2S-donor moieties, and NaHS, a 
prototypical H2S-generating agent, were described as activators of Kv7 potassium channels (Testai 
et al., 2016; Martelli et al., 2013a), a class of the voltage-gated potassium channels which plays a 
pivotal role in pain modulation (Zheng et al., 2013; Busserolles et al., 2016). A decreased 
expression of Kv7 channels contributes to neuropathic hyperalgesia (Rose et al., 2011) since 
channel activation inhibits C and Aδ fiber-mediated responses of dorsal horn neurons (Passmore et 
al., 2003) and reduces the ectopic generation of action potentials in neuropathic pain (Lang et al., 
2008). On these premises, Kv7 channel activators like retigabine are currently regarded as anti-
hyperalgesic compounds (Nodera et al., 2011; Blackburn-Munro and Jensen, 2003). 
Aim of the present work was to investigate the pharmacological profile of different isothiocyanates 
(the chemical structures are depicted in Scheme 1), after acute subcutaneous administration in 
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mouse models of chemotherapy-induced neuropathic pain evoked by paclitaxel and oxaliplatin (Di 
Cesare Mannelli et al., 2013; Fariello et al., 2014). In particular, allyl isothiocyanate, naturally 
occurring in many species of Brassicaceae (Citi et al., 2014), and the synthetic phenyl- and 
carboxyphenyl isothiocyanate were compared with NaHS. The pharmacodynamic involvement of 
H2S and Kv7 was studied.     
 
 
2. Methods 
 
2.1. Animals 
Male CD-1 albino mice (Envigo, Varese, Italy) weighing approximately 22–25 g at the beginning of 
the experimental procedure, were used. Animals were housed in CeSAL (Centro Stabulazione 
Animali da Laboratorio, University of Florence) and used at least 1 week after their arrival. Ten 
mice were housed per cage (size 26 × 41 cm); animals were fed a standard laboratory diet and tap 
water ad libitum, and kept at 23 ± 1 °C with a 12 h light/dark cycle, light at 7 a.m. All animal 
manipulations were carried out according to the Directive 2010/63/EU of the European parliament 
and of the European Union council (22 September 2010) on the protection of animals used for 
scientific purposes. The ethical policy of the University of Florence complies with the Guide for the 
Care and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication No. 
85-23, revised 1996; University of Florence assurance number: A5278-01). Formal approval to 
conduct the experiments described was obtained from the Animal Subjects Review Board of the 
University of Florence. Experiments involving animals have been reported according to ARRIVE 
guidelines (McGrath and Lilley, 2015). All efforts were made to minimize animal suffering and to 
reduce the number of animals used. 
 
2.2. Paclitaxel- and oxaliplatin-induced neuropathic pain models 
Mice treated with paclitaxel (2.0 mg kg-1) were injected i.p. on four alternate days (days 1, 3, 5 and 
7) (Polomano and Bennett., 2001). Paclitaxel was dissolved in a mixture of 10% saline solution and 
Cremophor EL, a derivative of castor oil and ethylene oxide that is clinically used as paclitaxel 
vehicle.  Mice treated with oxaliplatin (2.4 mg kg-1) were  administered i.p. on days 1-2, 5-9, 12-14 
(10 i.p. injections) (Cavaletti et al., 2001). Oxaliplatin was dissolved in 5% glucose solution. 
Control animals received an equivalent volume of vehicle. Behavioral tests were performed on day 
15. 
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2.3. Compound administrations and in vitro uses 
A-ITC, A-IC, P-ITC (Sigma-Aldrich, Milan, Italy) and CP-ITC (Fluorochem Ltd, Hadfield, UK) 
were dissolved in saline solution with 0.5% PEG. GYY4137 dichloromethane complex and NaHS 
(Sigma-Aldrich, Milan, Italy) were dissolved in saline solution. Morphine (S.A.L.A.R.S., Como, 
Italy) and pregabalin (3B Scientific Corporation, China) were dissolved in saline solution. 
Celecoxib (Sigma-Aldrich, Italy) and duloxetine (Sequoia Research, UK) were dissolved in 1% 
CMC. Compounds were acutely administered as follows. The doses of NaHS were chosen on the 
bases of previously published H2S releasing and antinociceptive properties (Distrutti et al., 2006; 
Martelli et al., 2013b) (1.33, 4.43, 13.31 and 38 µmol kg−1 corresponding to 0.1, 0.33, 1 and 3 mg 
kg-1 were administered by s.c. route or 4.43 nmol/mouse by i.c.v. route); P-ITC (1.33, 4.43 and 
13.31 µmol kg−1 s.c. or 4.43 nmol/mouse i.c.v.); CP-ITC, A-ITC and A-IC (1.33, 4.43 and 13.31 
µmol kg−1 s.c.); GYY4137 (4.43 µmol kg−1 s.c.). As reference compounds were used morphine 
(21.75 µmol kg−1; 7 mg kg−1 s.c.; Rashid et al., 2004), pregabalin (94.20 µmol kg−1; 15 mg kg−1 s.c.; 
Di Cesare Mannelli et al., 2015a), celecoxib (104.88 µmol kg−1; 40 mg kg−1 p.o.; Jiang et al., 2016) 
and duloxetine (50.43 µmol kg−1; 15 mg kg−1 p.o.; Di Cesare Mannelli et al., 2014). In additional 
experiment P-ITC, NaHS and GYY4137 (4.43 µmol kg−1) were administered s.c. in mixture with 
3.10 µmol kg−1 (200 mg kg−1) human Hb (Sigma-Aldrich, Italy) in saline solution and behavioral 
tests were carried out after 15, 30, 45 and 60 min from injection. The Kv7 potassium channel 
blocker XE991 (Tocris Bioscience, Italy; 2.66 µmol kg−1; 1 mg kg−1; Blackburn-Munro and Jensen, 
2003) was dissolved in saline solution and administered i.p. 15 min before the injection of tested 
compounds. The Kv7 potassium channel opener retigabine (Sequoia Research, UK; 65.93 µmol 
kg−1; 20 mg kg−1; Blackburn-Munro and Jensen, 2003; Miceli et al., 2008) was dissolved in 1% 
CMC and administered p.o.. 
In electrophysiological measurements, retigabine (Valeant Pharmaceuticals, USA) and CP-ITC 
were dissolved in DMSO, whereas NaHS (Sigma-Aldrich, Italy) was dissolved in water. In each 
experiment, the same volume of solvent present in the drug solution was added to the control 
solution; maximal concentration of DMSO (0.1%) was per se ineffective. A-ITC, A-IC and  P-ITC 
are liquid at room temperature, thus requiring no solvent addition in the respective control solution. 
Fresh drug stocks (at M concentration) were prepared daily or, as in the case of NaHS, twice daily. 
Fast solution exchanges (<1 s) were achieved, as previously reported (Ambrosino et al., 2015), by 
means of a cFlow 8 flow controller attached to a cF-8VS 8-valve switching apparatus and a MPRE8 
miniature flow outlet having an inside diameter of 360 µm and a mixing volume at the tip of 1-2 µl 
(Cell Microcontrols, Norfolk, VA, USA) positioned within 200 µm of the cell. 
2.4. Cold Plate Test 
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The animals were placed in a stainless steel box (12 cm × 20 cm × 10 cm) with a cold plate as floor. 
The temperature of the cold plate was kept constant at 4°C ± 1°C. Pain-related behavior (licking of 
the hind paw) was observed and the time (seconds) of the first sign was recorded. The cut-off time 
of the latency of paw lifting or licking was set at 60 seconds (Di Cesare Mannelli et al., 2013). 
 
2.5. Von Frey test  
Animals were placed in 10 cm × 10 cm Plexiglas boxes equipped with a metallic mesh floor, 20 cm 
above the bench. Animals were allowed to habituate themselves to their environment for 15 min 
before the test. An electronic Von Frey hair unit (Ugo Basile, Varese, Italy) was used: the 
withdrawal threshold was evaluated by applying forces ranging from 0 to 5 g with 0.2 g accuracy. 
Punctuate stimulus was delivered to the mid-plantar area of each posterior paw from below the 
mesh floor through a plastic tip and the withdrawal threshold was automatically displayed on the 
screen. The paw sensitivity threshold was defined as the minimum force required to elicit a robust 
and immediate withdrawal reflex of the paw. Voluntary movements associated with locomotion 
were not considered as a withdrawal response. Stimuli were applied to each anterior paw at 5 s 
intervals. Measurements were repeated 5 times and the final value was obtained by averaging the 5 
measurements (Ta et al., 2009). 
 
2.6. Hot-plate test  
Hot-plate test was carried out accordingly with O’Callaghan and Holzman (1975). Mice were 
placed inside a stainless steel container, thermostatically set at 52.5 ± 0.1 °C in a precision water-
bath from KW Mechanical Workshop, Siena, Italy. Reaction times (s) were measured with a stop-
watch before and at regular intervals up to a maximum of 60 min after treatment. The end point 
used was the licking of the fore or hind paws. Before treating animals tested compounds, a pretest 
was performed: those mice scoring below 12 and over 18 s were rejected. An arbitrary cutoff time 
of 45 s was adopted. 
 
2.7. Cell culture and transfection 
As previously described (Miceli et al., 2013), CHO cells were grown in DMEM medium 
supplemented with 10% FBS, 100 U mL-1 penicillin/streptomycin and 2 mM L-glutamine. The cells 
were kept in a humidified atmosphere at 37°C with 5% CO2 in 100 mm plastic Petri dishes. 
Twenty-four hours after plating on 35-mm glass coverslips (Carolina Biological Supply Co., 
Burlington, NC) coated with poly-L-lysine (Sigma, Milan, Italy), CHO cells were transiently 
transfected using Lipofectamine 2000 (Invitrogen, Milan, Italy), according to the manufacturer 
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protocols, with plasmids containing the cDNAs encoding for Kv7.2 or Kv7.2 and Kv7.3 (cDNA 
transfection ratio 1:1) and for the Enhanced Green Fluorescent Protein (Clontech, Palo Alto, CA; 
1/10 of the total cDNA), used as a transfection marker.  
 
2.8. Patch-clamp electrophysiology 
Currents from CHO cells were recorded at room temperature (20-22 °C) 1 day after transfection by 
using an Axopatch 200A (Molecular Devices) and the whole-cell configuration of the patch-clamp 
technique, with glass micropipettes of 3 to 5 MΩ resistance, as previously described (Ambrosino et 
al., 2015). The extracellular solution contained (in mM) 138 NaCl, 2 CaCl2, 5.4 KCl, 1 MgCl2, 10 
glucose, and 10 Hepes, pH 7.4 adjusted with NaOH; the pipette (intracellular) solution contained (in 
mM) 140 KCl, 2 MgCl2, 10 EGTA, 10 Hepes, 5 Mg-ATP, pH 7.3 to 7.4 adjusted with KOH. 
pCLAMP software (version 10.0.2) was used for data acquisition and analysis. Linear cell 
capacitance (C) was determined by integrating the area under the whole-cell capacity transient, 
evoked by short (5-10 ms) pulses from -80 to -75 mV with the whole-cell capacitance compensation 
circuit of the Axopatch 200A turned off. Currents were activated by 3-s voltage ramps from -80 mV 
to 0 mV at 0.1-Hz frequency. Current densities (expressed in pA/pF) were calculated by dividing 
currents at 0 mV by C. Currents were corrected offline for leakage currents using standard 
subtraction routines (Clampfit module of pClamp 10). In analogy to the reported effects of the 
prototypical Kv7 activator retigabine (Miceli et al., 2008), two parameters were used to quantify 
drug-induced effects: the percent of current potentiation at 0 mV, and the leftward shift of the 
membrane potential at which currents measured during drug application were identical to those 
recorded in control solution at -40 mV (Miceli et al., 2013); this latter parameter was arbitrarily 
defined as ∆V
-40. Both parameters were determined after 1-2-min drug application, a time sufficient 
for drug-induced effects to reach steady-state. Current activation and deactivation kinetics were 
analyzed by fitting the current traces to a single or to a double-exponential function of the following 
form: y = ampf  exp(-t/τf) + amps exp (-t/τs), where ampf and amps indicate the amplitude of the fast 
and slow exponential components respectively, whereas τf and τs indicate the time constants of 
these components, as previously described (Soldovieri et al., 2007). 
 
2.9. Statistical analysis 
Behavioral measurements were performed on 16 mice for each treatment carried out in 2 different 
experimental sets. Results were expressed as mean ± S.E.M. The analysis of variance of behavioral 
data was performed by one way ANOVA, a Bonferroni's significant difference procedure was used 
as post-hoc comparison. P values of less than 0.05 or 0.01 were considered significant. Statistically 
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significant differences in electrophysiology data were evaluated with the Student t test, or with 
ANOVA followed by the Student-Newman-Keuls test when multiple groups were compared, with 
the threshold set at P<0.05. Investigators were blind to all experimental procedures. Data were 
analyzed using the “Origin 9” software (OriginLab, Northampton, USA). The area under the curve 
(AUC) of the antinociceptive effects was calculated using the same software, evaluating the data 
from 0–60 min. 
 
 
3. Results 
 
3.1. Behavioral studies 
On day 15, paclitaxel-treated mice showed a significantly decreased latency to pain-related 
behaviors induced by a cold stimulus (11.5 ± 0.9 s) compared to control mice (23.4 ± 1.7 s) treated 
with vehicle (Figure 1). The effect of single administration s.c. of three different doses of P-ITC, 
CP-ITC, A-ITC and NaHS on paclitaxel-treated mice is shown in Figure 1a, b, c and d, 
respectively. P-ITC is active starting from 4.43 µmol kg-1. The dose of 13.31 µmol kg-1 was 
significant starting 15 min after administration, the effect lasted until 45 min. CP-ITC (1.33 µmol 
kg-1) increased pain threshold only 15 min after administration. Otherwise, 4.43 µmol kg-1 and 
13.31 µmol kg-1 CP-ITC increased the licking latency long lastingly. A-ITC (4.43 and 13.31 µmol 
kg-1) was active between 15 and 45 min after administration. NaHS was active in paclitaxel-treated 
mice starting from the dose of 4.43 µmol kg-1, plateauing between 30 min and 45 min after 
administration. The highest dose was lesser effective. 
The pain threshold measurements of oxaliplatin-treated animals (Cold plate test) is shown in Figure 
2. On day 15, oxaliplatin decreased the licking latency to 12.6 ± 0.7 s in comparison to control mice 
(21.5 ± 1.2 s). The lower dose of P-ITC induced a slight effect whereas 4.43 µmol kg-1 and 13.31 
µmol kg-1 significantly increased the licking latency starting 15 min after administration and 
reaching a maximum effect 30 min after administration. CP-ITC (1.31 µmol kg-1) improved pain 
threshold between 15 and 30 min. Oxaliplatin-induced hypersensitivity was fully abolished by the 
high doses of CP-ITC (4.43 µmol kg-1 and 13.31 µmol kg-1). NaHS (13.31 µmol kg-1) was effective 
between 15 and 45 min. The higher dose was lesser long-lasting. Morphine (21.75 µmol kg-1 s.c.) 
did not increase the licking latency of oxaliplatin-treated mice. Celecoxib (104.88 µmol kg-1 p.o.) 
and pregabalin (94.20 µmol  kg-1 s.c.) significantly increased pain threshold only 15 min after 
administration. Duloxetine (50.43 µmol kg-1 p.o.) induced a maximum effect 30 min after 
administration (Figure 2). Effects of these reference compounds on paclitaxel-induced neuropathic 
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pain are already published. In particular, pregabalin and duloxetin showed similar efficacy than in 
oxaliplatin model (Ito et al., 2012); on the contrary, morphine (Xu et al., 2011) was partially active 
against paclitaxel (differently from oxaliplatin) whereas celecoxib did not (Ito et al., 2012). 
P-ITC, CP-ITC and NaHS showed similar efficacy against paclitaxel- and oxaliplatin-dependent 
hypersensitivity when evoked by mechanical stimulus (Von Frey test, Supplementary Figure S1 and 
S2).  
Figure 3a shows the comparison between the responses to acute administration s.c. of A-ITC and A-
IC on oxaliplatin-treated mice. A-ITC (13.31 µmol kg-1) increased licking latency up to control 
level. On the contrary, A-IC, the analogue molecule without the sulfhydryl group (Scheme 1), was 
not active after administration s.c. of the same dosage. In Figure 3b, the enhancement of pain 
threshold induced by a single administration of NaHS (13.31 µmol kg-1), P-ITC (4.43 µmol   kg-1), 
CP-ITC (4.43 µmol   kg-1), A-ITC (4.43 µmol kg-1) expressed as AUC (0 – 60 min) is shown in 
comparison to oxaliplatin-treated mice. The H2S-binding molecule Hb (3.1 µmol kg-1 s.c.), co-
administered with the H2S donors, was able to fully prevent the anti-hypersensitive efficacy. Hb per 
se was ineffective (Figure 3b). Similar results were obtained by the non-isothiocyanate H2S donors 
GYY4137 (4.43 µmol kg-1 s.c.; GYY) (Figure 3b). In the Supplementary Figure S3, effects over 
time of this morpholine-derivative were shown in the absence and in the presence of Hb. 
Pain relieving activity of NaHS (13.31 µmol kg-1 s.c.), P-ITC, CP-ITC and A-ITC (all at 4.43 µmol 
kg-1 s.c.) was fully prevented by the administration i.p. of the Kv7 potassium channel blocker  
XE991 (2.66 µmol kg-1) as shown in Figure 4a (AUC values; 0 – 60 min). The relevance of Kv7 in 
pain modulation was confirmed through the effectiveness showed by the Kv7 opener retigabine 
(65.93 µmol kg-1 p.o.) in oxaliplatin-treated mice (Figure 4b). XE991 reverted retigabine efficacy 
without altering the pain threshold per se (Figure 4b). A dose-response curve of XE-991 per se 
effects on oxaliplatin-induced hypersensitivity is shown in the Supplementary Figure S4. 
To evaluate the central component of the anti-neuropathic effect of H2S donor molecules, the 
efficacy of NaHS (13.31 nmol/mouse) and P-ITC (4.43 nmol/mouse) was evaluated after i.c.v. 
administration in oxaliplatin-treated mice (Figure 4c). Both compounds increased the pain threshold 
up to control group levels peaking 30 min after administration. These effects were fully prevented 
by the pre-administration of XE991 i.p. (Figure 4c).  
Neither NaHS (13.31 µmol kg-1 s.c.) nor A-ITC and P-ITC (both 4.43 µmol kg-1 s.c.) were able to 
influence the normal pain threshold of naïve animals as evaluated by Hot plate test using a thermal 
noxious stimulus able to highlight analgesic effects (Supplementary Figure S5). 
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3.2. Electrophysiological studies 
Given the in vivo data showing that the Kv7 channel blocker XE991 antagonized the pain-relieving 
activity of H2S donors, the ability of these drugs to directly influence the activity of Kv7 channels 
involved in pain information processing was also investigated. To this aim, patch-clamp 
experiments in CHO cells transfected with Kv7.2 and Kv7.3 cDNAs were carried out.  In response 
to voltage ramps from -80 mV to 0 mV, heteromeric channels formed by Kv7.2/3 subunits elicit 
robust voltage-dependent, outwardly rectifying K+ currents. Perfusion for 1-2 min with the Kv7 
opener retigabine (0.01 mM) led to an increase in maximal current of ~ 2-fold, and to a leftward 
shift in the threshold potential of current activation of ~ -20 mV (Figure 5). Using an identical 
experimental paradigm, perfusion with NaHS (0.01-10 mM), A-ITC (0.01-10 mM), P-ITC (1-100 
mM), or CP-ITC (0.01-10 mM) dose-dependently increased maximal current size at 0 mV (Figure 
5a and 5b) and shifted the ∆V
-40 toward more negative membrane potential values (Figure 5a and 
5c); notably, the effect of CP-ITC on ∆V
-40, although smaller than that observed with retigabine, 
was significantly greater than that of NaHS. By contrast, no effect was observed upon perfusion 
with 1-10 mM A-IC, suggesting that the presence of a thiol group was essential for the functional 
effects observed on Kv7 currents by A-ITC (Scheme 1). Finally, CP-ITC appeared more efficacious 
and potent than P-ITC in potentiating Kv7.2/3 maximal currents and negatively-shifting the ∆V
-40; 
this latter result is consistent with the higher H2S levels produced by CP-ITC when compared to P-
ITC, thus highlighting a relevant role for the carboxyl group in this process (Martelli et al., 2014). 
K+ currents carried by Kv7.2/3 channels displayed activation kinetics which could be fitted by a 
sum of two exponential functions (Wang et al., 1998; Castaldo et al., 2002), with a fast and a slow 
time constants (τf and τs, respectively) (Supplementary Figure S6, panels a and b); at any given 
potential above -40 mV, the relative amplitude of the fast component, called Af, largely dominated 
over that of the slow component, called As; thus, the ratio of Af and As, expressed as Af/(Af+As), 
was around 1 at all potentials investigated (Supplementary Figure S6, panel c). Perfusion with 1 
mM CP-ITC failed to modify current activation rates, as no change was detected in either τf or τs 
before and after drug exposure at any given potential between -40 mV to +40mV. On the other 
hand, the H2S donor significantly decreased the ratio between the two components (described by 
Af/Af+As) for potentials ≥ -20 mV; this was due to a drug-dependent increase in the absolute 
amplitude of the slow component, virtually absent in control conditions. Perfusion with 1 mM CP-
ITC also markedly reduced current deactivation kinetics (Supplementary Figure S6, panels d and e).  
In rat hippocampal presynaptic terminals (Martire et al., 2004) and in large fibers of the rat sciatic 
nerve (Schwarz et al., 2006), functional Kv7.2 homomers have also been described; when compared 
to heteromeric Kv7.2/3 channels, Kv7.2 currents are 4-6 times smaller, activate at slightly more 
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positive membrane voltages (Wang et al., 1998), and display a higher sensitivity to the pore blocker 
TEA (Hadley et al., 2000). To investigate whether H2S donors differentially affected Kv7.2 
homomers when compared to Kv7.2/3 heteromers, electrophysiological experiments were also 
carried out in CHO cells transfected only with Kv7.2 cDNA. As shown in Supplementary Figure 
S7, Kv7.2 currents showed a pharmacological profile very similar to that of Kv7.2/3 currents, being 
potentiated (though with a lower potency and efficacy when compared to retigabine) by 1 mM 
NaHS, A-ITC, P-ITC, or CP-ITC, and being unaffected by 1 mM A-IC.  
 
 
4. Discussion 
 
The development of painful neuropathies is a severe dose-limiting side effect of commonly used 
chemotherapeutic agents including taxanes, vinca alkaloids and platinum agents (Ward et al., 2014; 
Watkins et al., 2005). Paclitaxel-induced neurotoxicity is characterized by numbness, tingling and 
burning pain (Dougherty et al., 2004); repeated oxaliplatin administrations induce a chronic 
neurological syndrome that persists between and after treatment (Beijers et al., 1999; Souglakos et 
al., 2002) negatively influencing patient’s quality of life. The pharmacological management 
of chemotherapy-induced neuropathy remains largely ineffective (Hershman et al., 2014).  
The present results show the pain relieving efficacy of novel isothiocyanate-based H2S-donors, 
along with the well-known reference compounds NaHS and GYY4137, in animal models of 
neuropathic pain induced by anticancer drugs. P-ITC, CP-ITC and A-ITC reduce the 
hypersensitivity to a cold non-noxious stimulus (allodynia-related measurement) after the acute 
systemic administration of very low doses both in paclitaxel and oxaliplatin-treated animals 
(effectiveness has been demonstrated also using a mechanical non-noxious stimulus, both the 
responses are strictly related to the neuropathic condition; Di Cesare Mannelli et al. 2013) Because 
of the similar pharmacological profile shown in the two models, further experiments were carried 
out in the best characterized neuropathy model, namely that evoked by the platin derivative.  
When compared to duloxetine and pregabalin, two molecules currently in clinical use to reduce the 
symptoms of chemotherapy-induced neuropathy (Hershman et al., 2014), isothiocyanates show 
similar efficacy at 10-times lower doses; morphine is ineffective against oxaliplatin-dependent pain. 
NaHS, a prototypical H2S-donor, shows similar efficacy as isothiocyanates, despite being less 
potent. Both synthetic (Martelli et al. 2014) and naturally-occurring (Citi et al., 2014) 
isothiocyanates act as H2S-releasing compounds, and our results are consistent with an involvement 
of this gasotransmitter in the antinociceptive effects shown by these molecules.  The H2S-binding 
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molecule Hb (Pietri et al., 2011) fully prevented the anti-neuropathic efficacy of P-ITC, CP-ITC, A-
ITC and NaHS, as well as of GYY4137, a morpholin-derivative able to slowly release H2S both in 
vitro and in vivo (Li et al., 2008). Moreover, A-IC, the corresponding isocyanate of A-ITC, unable 
to release H2S, was completely ineffective against oxaliplatin-induced neuropathy. Efficacy of P-
ITC and NaHS was also measurable after i.c.v. administration, suggesting a central component of 
the H2S donors-mediated anti-neuropathic property. Independently by the route of administration, 
these compounds were effective at very low doses. Characteristically, while some compounds like 
P-ITC and CP-ITC seem to reach a maximal effect beyond which the dose increase is not 
significant, the anti-neuropathic effects of the highest doses of NaHS and A-ITC were less evident 
when compared to lower doses. Although this bell-shaped dose-dependence possibly involves the 
complex pharmacokinetic profile of specific H2S donors, it should be highlighted that a similar 
phenomenon has been also reported for the mitochondrial effects of H2S. In fact, low concentrations 
of H2S donors stimulate the mitochondrial electron transport, evoke protective effects maintaining 
mitochondrial function, protecting mitochondrial DNA integrity, and inhibiting mitochondrial 
protein oxidation (Ahmad et al., 2016). On the contrary, elevation of H2S concentrations beyond a 
certain concentration range becomes cytotoxic, pro-oxidant, and suppresses mitochondrial electron 
transport (Szabo et al., 2014). 
The lipid-soluble nature of H2S enables this gasotransmitter to easily reach its molecular targets on 
the plasma membrane, inside the cytosol or in intracellular organelles. Its characteristic membrane 
permeability, together with its unique chemical reactivity with certain types of macromolecules in 
different types of cells, makes H2S a pleiotropic and powerful signaling molecule (Wallace and 
Wang, 2015). Voltage-gated potassium channel subunits encoded by the Kv7 subfamily have been 
shown to mediate a large part of the H2S-induced cardiovascular effects through an effect on Kv7.4 
subunits (Schleifenbaum et al., 2010; Martelli et al., 2013a). The Kv7 gene family includes five 
members (Kv7.1-5), each showing a specific tissue distribution and functional role (Soldovieri et 
al., 2011). In particular, heteromeric assembly of Kv7.2 and Kv7.3 subunits is believed to provide a 
major contribution to a sub-threshold slowly-activating and deactivating, and non-inactivating K+ 
current known as the M-current (Wang et al., 1998), which limits repetitive firing and causes spike-
frequency adaptation (Soldovieri et al., 2011). Heteromeric Kv7.2/3 channels appear as the main 
players in pain information processing, being abundantly expressed in nodes of Ranvier and the cell 
bodies of large sensory neurons as well as in the dorsal horns, the thalamus and the cortex (Wang 
and Li, 2016). Notably, although Kv7.5 subunits are also abundantly expressed in C-fibers and 
control excitability of nociceptive neurons (King and Scherer, 2012), the pharmacological profile of 
the M currents recorded from nociceptive DRG neurons speaks against a strong contribution of 
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Kv7.5 (Du and Gamper, 2013). Inhibition of Kv7 channels with XE-991, a specific and potent 
blocker of the currents carried by Kv7 channels (Wang et al., 1998), leads to hyperexcitability of 
primary sensory neurons (Zheng et al., 2013). On the other hand, retigabine, an activator of 
neuronal Kv7 channels (Miceli et al., 2008), was neuroprotective against cisplatin- (Nodera et al., 
2011) and oxaliplatin- (Abd-Elsayed et al., 2015) induced neuropathy, decreased osteoarticular and 
neuropathic pain (Li et al., 2015; Brown and Passmore, 2009), and suppressed the excitability of 
nociceptive cold-sensing trigeminal ganglion neurons (Abd-Elsayed et al., 2015). Moreover, 
flupirtine, a retigabine-analogue also acting as a Kv7 activator (Martire et al., 2004) suppressed 
axonal hyperexcitability of peripheral nerve exposed to oxaliplatin (Sittl et al., 2010). All these 
evidence point toward a crucial role of Kv7 channels in several models of persistent pain. In the 
present study, retigabine is shown to effectively protect against oxaliplatin-dependent pain, and the 
Kv7 blocker XE991 fully counteracted the pain relieving effects of retigabine as well as of 
isothiocyanates and NaHS administered by both systemic or i.c.v. routes. Importantly, XE991 
reverted H2S donors effects at dosages that did not modify oxaliplatin-hypersensitivity per se 
(present data). Furthermore, XE991 did not show anti-nociceptive properties since it did not modify 
the normal pain threshold of naïve animals (Blackburn-Munro et al., 2003; Hayashi et al., 2014). 
These data led us to hypothesize that H2S, by activating Kv7 channels, reduces neuronal 
hyperexcitability both in DRG and in central neurons, thus normalizing the altered 
electrophysiological activity occurring during  chemotherapy-induced neuropathic pain (Di Cesare 
Mannelli et al., 2015b) 
Patch-clamp experiments in CHO cells heterologously-expressing Kv7.2 and Kv7.3 cDNAs 
revealed that Kv7.2/3 heteromeric currents showed concentration-dependent activation by H2S-
releasing isothiocyanates, suggesting that these channels mediate at least some of the anti-
hypersensitive effects exerted in vivo by these compounds. Biophysical analysis of the changes 
introduced by the most effective H2S donor herein investigated (CP-ITC) on Kv7.2/3 activation and 
deactivation kinetics are suggestive of a drug-induced increased stabilization of the open 
configuration of the channel, leading to a decreased rate of channel deactivation, and a facilitation 
of channel opening by voltage. The present experiments do not allow to discriminate whether H2S 
activated Kv7.2/3 currents by interacting directly with the channel subunits or whether intermediate 
messengers are involved. It would be interesting to verify a possible interaction of H2S with radical 
oxygen species (ROS), given the fact that H2O2 markedly increase currents formed by Kv7.2, 
Kv7.3, and Kv7.4 channels (Gamper et al. 2006). In Kv7.4 channels, a conserved cysteine triplet in 
the S2–S3 linker was identified as critical for this pharmacological effect; whether this same site is 
also involved in the described effects of H2S on Kv7.2 /3 channels is still unknown.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
It should be noted that all the isothiocyanates used in this study, along with the reference H2S donor 
NaHS, showed anti-neuropathic effects. However, they exhibited different degrees of efficacy and 
potency (in the in vivo experiments and in the electrophysiological studies), not clearly related with 
their H2S-releasing profiles. Slow H2S-donors, such as GYY4137, are often more effective than 
rapid donors, such as NaHS, suggesting that long-lasting generation of relatively lower 
concentrations of H2S can be preferable for certain pharmacological effects (Li et al., 2008). 
Moreover, the isothiocyanates used in this study are not “spontaneous” H2S-donors: indeed, the 
H2S-release from these compounds is triggered by the presence of organic thiols such as L-cystein 
(Martelli et al., 2014). Thus, this process can be “smartly” promoted in biological environments by 
a large availability of endogenous organic thiols (and perhaps by other metabolic reactions), but can 
be also influenced by variables linked to different experimental models which can make difficult the 
quantitative correlation between H2S-release and pharmacological effects. Finally, even 
pharmacokinetic aspects, concerning the ability of the H2S-prodrugs to reach the pharmacological 
target, may play a role. 
The emerging data on the biological effects of H2S, and the etiopathogenetic roles of both excessive 
and defective H2S biosynthesis in some diseases, support two main approaches for the development 
of sulfide-based therapeutics: suppression of endogenous sulfide formation by inhibitors of CSE 
and CBS, and gaseous H2S or H2S-releasing compounds (sulfide donors). The formers (DL-
propargylglycine and β-cyanoalanine) have low potency and a questionable selectivity (Szabò, 
2007). Concerning the latter compounds, excluding gaseous H2S for its poor safety, H2S equivalents 
or releasing agents (i.e. donors) are becoming important research tools (Zhao et al., 2014). In the 
past, some series of different H2S pro-drugs were developed (Zheng et al., 2015; Zhao et al., 2014) 
often obtaining a limited control of gas release. Presently, there is still scarce heterogeneity of H2S-
releasing moieties endowed with satisfactory pharmacological and chemical (stability) features. 
Isothiocyanate exhibit interesting H2S-releasing properties which can be usefully employed for 
therapeutic purposes. The effectiveness of allyl isothiocyanate, mainly obtained from the seeds of 
Brassica nigra L., raises the intriguing possibility to exploit the plant kingdom as a source of H2S-
based therapeutics against neuropathic pain.  
In this perspective, the present study demonstrates that H2S-releasing compounds, such as the “gold 
standard” GYY4137 or the novel isothiocyanates, promote H2S-mediated activation of Kv7 
channels and may represent an exciting and innovative approach to drug-resistant forms of pain 
such as chemotherapy-induced neuropathies. 
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Figure captions 
 
Figure 1. Effects of H2S donors on paclitaxel-induced neuropathic pain. The response to a 
thermal stimulus was evaluated by the Cold plate test measuring the latency (s) to pain-related 
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behaviors (lifting or licking of the paw). Mice were treated with paclitaxel (2.0 mg kg−1 i.p.) on four 
alternate days (days 1, 3, 5 and 7) and the acute tests were performed on day 15. a) P-ITC, b) CP-
ITC, and c) AITC (1.33, 4.43 and 13.31 µmol kg−1) NaHS (4.43, 13.31 and 38 µmol kg−1) were 
administered s.c.. Measurements were performed 15, 30, 45 and 60 min after injection. Control 
mice were treated with vehicle. Each value represents the mean of 16 mice per group, performed in 
2 different experimental sets. *P<0.05 and **P<0.01 vs paclitaxel + vehicle treated animals.  
 
Figure 2. Effects of H2S donors on oxaliplatin-induced neuropathic pain. The response to a 
thermal stimulus was evaluated by the Cold plate test measuring the latency (s) to pain-related 
behaviors (lifting or licking of the paw). Mice were daily treated i.p. with oxaliplatin 2.4 mg kg−1. 
Tests were performed on day 15. a) P-ITC, b) CP-ITC (both at 1.33, 4.43 and 13.31 µmol kg−1), and 
c) NaHS (4.43, 13.31 and 38 µmol kg−1) were administered s.c.. Measurements were performed 15, 
30, 45 and 60 min after injection. The reference compounds d) morphine (21.75 µmol kg−1 s.c.), 
celecoxib (104.88 µmol kg−1 s.c.), duloxetine (50.43 µmol kg−1 p.o.) and pregabalin (94.20 µmol 
kg−1 p.o.) were administered, pain threshold was assessed 15, 30, 45 and 60 min after injection. 
Control mice were treated with vehicle. Each value represents the mean of 16 mice per group, 
performed in 2 different experimental sets. *P<0.05 and **P<0.01 vs oxaliplatin + vehicle treated 
mice.  
 
Figure 3. Role of H2S in the relief of oxaliplatin-induced neuropathic pain. The latency (s) to 
pain-related behaviors (lifting or licking of the paw) was measured by the Cold plate test. Mice 
were daily treated i.p. with oxaliplatin (2.4 mg kg−1) and behavior was measured on day 15. a) A-
ITC (1.33, 4.43 and 13.31 µmol kg−1 s.c.) was compared with A-IC (13.31 µmol kg−1 s.c.). b) NaHS 
(13.31 µmol kg−1 s.c.), P-ITC, CP-ITC, A-ITC and the morpholine derivative GYY4137 (GYY) (all 
at 4.43 µmol kg−1 s.c.) were administered alone or in mixture with Hb (3.10 µmol kg−1). The 
histogram shows the average of resulting AUC. Control mice were treated with vehicle. Each value 
represents the mean of 16 mice per group, performed in 2 different experimental sets. *P<0.05 and 
**P<0.01 vs oxaliplatin + vehicle treated mice. 
 
Figure 4. Involvement of Kv7 channels in H2S-mediated anti-neuropathic effect. The latency 
(s) to pain-related behaviors (lifting or licking of the paw) was measured by the Cold plate test. 
Mice were daily treated i.p. with oxaliplatin (2.4 mg kg−1) and behavior was measured on day 15. a) 
P-ITC, CP-ITC, A-ITC (4.43 µmol kg−1) and NaHS (13.31 µmol kg−1) were administered s.c.. 
XE991 (2.66 µmol kg−1) was administered i.p. 15 min before H2S-donors. The histograms show the 
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average of resulting AUC. b) Retigabine (2.66 µmol kg−1) was administered p.o. in the absence and 
in the presence of a pretreatment (15 min before) with XE991 (2.66 µmol kg−1 i.p). c) P-ITC (4.43 
µmol/mouse) and NaHS (13.31 µmol/mouse) were administered i.c.v. in the absence and in the 
presence of a pretreatment (15 min before) with XE991 (2.66 µmol kg−1 i.p.). Control mice were 
treated with vehicle. Each value represents the mean of 16 mice per group, performed in 2 different 
experimental sets. *P<0.05 and **P<0.01 vs oxaliplatin + vehicle treated mice. 
 
Figure 5. Effect of H2S donors on Kv7.2/3 currents heterologously-expressed in CHO cells. a) 
Macroscopic currents recorded in response to a voltage ramp from -80 to 0 mM in CHO cells 
expressing Kv7.2/7.3 channels in control solution (CTL) or after perfusion with the maximal 
concentration tested of each of the following compound (in mM): 0.01 retigabine (RTG), 10 NaHS 
(NaHS), 10 allyl-isocyanate (A-IC), 10 allyl-isothiocyanate (A-ITC), 100 phenyl-isothiocyanate (P-
ITC), or 10 3-carboxyphenyl-isothiocyanate (CP-ITC), as indicated. Current scale: 200 pA; time 
scale: 200 ms. b and c) Quantification of the effects prompted by each compound on peak current 
increase (b) or ∆V
-40 (c). Single asterisks indicate, for each drug, values significantly (P<0.05) 
different versus controls; double and triple asterisks indicate values significantly different (P<0.05) 
versus controls and versus values recorded upon perfusion of a lower drug concentration. The 
numbers on top of each bar indicate the number of measurements, each from a different cell. 
  
 
Supplementary material 
Supplementary Figure legends 
 
Supplementary Figure S1. Effects of H2S donors on paclitaxel-induced neuropathic pain. The 
response to a mechanical stimulus was evaluated by the Von Frey test measuring the withdrawal 
threshold (g). Mice were treated with paclitaxel (2.0 mg kg−1 i.p.) on four alternate days (days 1, 3, 
5 and 7) and the acute tests were performed on day 15. P-ITC (4.43 µmol kg−1), CP-ITC (4.43 µmol 
kg−1), and  NaHS (13.31 µmol kg−1) were administered s.c.. Measurements were performed 15, 30, 
45 and 60 min after injection. Control mice were treated with vehicle. Each value represents the 
mean of 12 mice per group, performed in 2 different experimental sets. *P<0.05 and **P<0.01 vs 
paclitaxel + vehicle treated animals.  
 
Supplementary Figure S2. Effects of H2S donors on oxaliplatin-induced neuropathic pain. The 
response to a mechanical stimulus was evaluated by the Von Frey test measuring the withdrawal 
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threshold (g). Mice were daily treated i.p. with oxaliplatin 2.4 mg kg−1. Tests were performed on 
day 15. P-ITC (4.43 µmol kg−1), CP-ITC (4.43 µmol kg−1), and  NaHS (13.31 µmol kg−1) were 
administered s.c.. Measurements were performed 15, 30, 45 and 60 min after injection. Control 
mice were treated with vehicle. Each value represents the mean of 12 mice per group, performed in 
2 different experimental sets. *P<0.05 and **P<0.01 vs oxaliplatin + vehicle treated mice.  
 
Supplementary Figure S3. Role of H2S in the relief of oxaliplatin-induced neuropathic pain. 
The latency (s) to pain-related behaviors (lifting or licking of the paw) was measured by the Cold 
plate test. Mice were daily treated i.p. with oxaliplatin (2.4 mg kg−1) and behavior was measured on 
day 15. Effect of the morpholine-derivative GYY4137 (4.43 µmol kg−1 s.c.) administered alone or 
in mixture with Hb (3.10 µmol kg−1). Control mice were treated with vehicle. Each value represents 
the mean of 16 mice per group, performed in 2 different experimental sets. *P<0.05 and **P<0.01 
vs oxaliplatin + vehicle treated mice. 
 
Supplementary Figure S4. Effects of XE991 on oxaliplatin-induced neuropathic pain. The 
latency (s) to pain-related behaviors (lifting or licking of the paw) was measured by the Cold plate 
test. Mice were daily treated i.p. with oxaliplatin (2.4 mg kg−1) and behavior was measured on day 
15. Effects of XE991 (2.66, 7.98 and 26.60 µmol kg−1) after administered i.p. administration. 
Control mice were treated with vehicle. Each value represents the mean of 10 mice per group, 
performed in 2 different experimental sets.  
 
Supplementary Figure S5. Effects of H2S donors on normal pain threshold. Compounds 
(NaHS, A-ITC and P-ITC) were injected s.c. Pain-related behavior (i.e. lifting and licking of the 
hind paw) were observed in the Hot Plate test, the time (s) of the first sign was recorded. 
Measurements were performed before and after treatments over time. Each value represents the 
mean of 10 mice per group, performed in 2 different experimental sets. 
 
Supplementary Figure S6. Effect of CP-ITC on activation and deactivation kinetics of Kv7.2/3 
currents expressed in CHO cells. a) Superimposed macroscopic Kv7.2/3 current traces recorded 
in response to the indicated voltage protocol in control solution (black trace) or after perfusion with 
1 mM CP-ITC (gray trace). b) Kv7.2/3 current activation time constants (τf, empty symbols; τs, 
filled symbols) recorded in control solution (CTL, circles) or upon perfusion with 1 mM CP-ITC 
(CP-ITC, squares). c) Relative amplitudes of the fast (Af) and slow (As) current activation 
components, expressed as Af/Af+As, recorded in control solution (circles) or upon perfusion with 1 
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mM CP-ITC (squares). Asterisks denote values significantly different from the corresponding 
control values (p<0.05). d) Superimposed macroscopic Kv7.2/3 current traces recorded in response 
to the indicated voltage protocol in control solution (CTL, black trace) or after perfusion with 1 mM 
CP-ITC (CP-ITC, gray trace). e) Deactivation time constants (τ) measured in control solution 
(circles) or upon perfusion with 1 mM CP-ITC (squares). Asterisks denote values significantly 
different from the corresponding control values (P<0.05). 
 
Supplementary Figure S7. Effect of H2S donors on Kv7.2 currents heterologously-expressed 
in CHO cells. a) Macroscopic currents recorded in response to a voltage ramp from -80 to 0 mM in 
CHO cells expressing Kv7.2 channels in control solution (CTL) or after perfusion with (in mM) 
0.01retigabine (RTG), 1 NaHS, 1 A-ITC, or 1 CP-ITC, as indicated. Current scale: 100 pA; time 
scale: 200 ms. b and c) Quantification of the effects of each compound on maximal current density 
(b; data are expressed as % of controls, measured before drug exposure) or as ∆V
-40 (c; data are 
expressed in mV). Single asterisks indicate values significantly different (P<0.05) versus controls; 
double asterisks indicates values significantly different (P<0.05) versus both control and the 
reference compound NaHS. In b), the numbers on top of each bar indicate the number of 
measurements, each from a different cell. 
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• Natural and synthetic isothiocyanates reduce oxaliplatin-dependent neuropathic pain 
• The efficacy is related to the property of releasing the gasotransmitter H2S 
• The pain relieving effect is reverted by the Kv7 potassium channel blocker XE991 
• H2S-releasing isothiocyanates potentiate Kv7.2/3 currents 
 
 
